NCT00246467View on ClinicalTrials.gov

One Year Study to Evaluate Three Different Adjuvanted Doses of the Recombinant Plague Vaccine (rF1 and rV Antigens)

PHASE1CompletedINTERVENTIONAL
Enrollment

123

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

April 30, 2007

Study Completion Date

April 30, 2007

Conditions
Plague
Interventions
BIOLOGICAL

Alhydrogel

BIOLOGICAL

rF1 and rV protein antigens

Trial Locations (10)

20006

Accelovance, Washington D.C.

32607

Florida Medical Research Institute, Gainesville

32935

Accelovance, Melbourne

33143

Miami Research Associates, Miami

33781

Radiant Research, Pinellas Park

35802

Accelovance, Huntsville

46601

Accelovance, South Bend

73112

Lynn Health Science Institute, Oklahoma City

79106

Accelovance, Amarillo

CF48 4DR

Simbec Research Limited, Merthyr Tydfil

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

PharmAthene UK Limited

INDUSTRY

NCT00246467 - One Year Study to Evaluate Three Different Adjuvanted Doses of the Recombinant Plague Vaccine (rF1 and rV Antigens) | Biotech Hunter | Biotech Hunter